MarginsXMarginsX
Home › Markets › Health Care › PRQR

ProQR Therapeutics N.V. (PRQR)

PRQR trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$1.18
-16.31% on the day
Market cap
$166.5M
Micro cap
Revenue · 2025
$17.6M
No prior year to compare
Net income · 2025
-$46.6M
-265.2% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC filing XBRL, 20-F (ifrs-full:RevenueFromContractsWithCustomers), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1612940/000110465926026713/0001104659-26-026713-index.htm. Net income: SEC 20-F (ifrs-full:ProfitLossAttributableToOwnersOfParent), fiscal year ended 2025-12-31. Converted from EUR at 0.9048 per USD (today's ECB or Federal Reserve reference rate).

Profile

FieldValue
TickerPRQR on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryNetherlands
IPO year2014
SEC CIK0001612940

Financials · 2025

LineValue
Revenue$17.6M
Net income-$46.6M
Operating income-$48.0M
Net margin-265.2%
Operating margin-273.1%
Revenue growthNo prior-year revenue to compare
Cash$102.1M
Total assets$124.6M
P/E (computed)Net income was not positive
P/S (computed)9.5×

Reported in EUR; shown in US dollars.

Warning signs

Cash runway
21.0 months
$102.1M cash at December 31, 2025
Share count, 1 year
See the dilution note
Going-concern doubt
No
20-F filed March 12, 2026
Insider net buying, 12 months
$1.3M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.20-F 2026-03-12
Cash and burn$102.1M cash; operating cash flow -$14.6M a quarter.Report 2025-12-31
Shares outstanding105,361,064 (2025-12-31). the newest SEC cover-page count is from 2025-12-31; shares issued since then are not in these figures.Cover page 2025-12-31
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 2 424B5 takedowns, 1 at the marketLatest 2026-06-26
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorKPMG Accountants N.V., Amstelveen, NetherlandsPCAOB Form AP 2026-04-16
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $1.3M, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Annual results

Fiscal yearRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
FY 2025
2025-12-31
$17.6M-$46.6M-$58.3M$102.1M$5.4M$17.6M20-F 2026-03-12

From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

The SEC filing list did not load in time for this page. It is on SEC EDGAR and in the full dossier.

Price moves

WindowReturn
1 week+4.4%
1 month-4.7%
3 months-23.8%
Year to date-30.2%
1 year-34.7%
From 52-week high-42.4%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
ELDNEledon Pharmaceuticals Inc.$1.97-6.86%$166.4M
PYXSPyxis Oncology Inc.$1.41-10.76%$168.6M
ORMPOramed Pharmaceuticals Inc.$3.90+5.12%$169.6M
ANTXAN2 Therapeutics Inc.$4.47-1.76%$169.6M
ADCTADC Therapeutics SA Common Shares$1.25-6.72%$159.7M
IFRXInflaRx N.V.$1.18+0.85%$173.9M
KRROKorro Bio Inc.$12.71-6.61%$174.5M
BBOTBridgeBio Oncology Therapeutics Inc. Common Stock$1.98-7.48%$158.9M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier